DMAC - NASDAQ

DiaMedica Therapeutics Inc.

DMAC·NASDAQ

$5.70

-1.2%

HealthcareBiotechnology

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$307.13M

EPS-0.7000

P/E Ratio-8.14

Earnings Date08/11/2026

61.37M

Assets

32%

3Y+78.0%

5Y+118.0%

10Y+3177.0%

5.26M

Total Liabilities

-7%

3Y+105.0%

5Y+153.0%

10Y+739.0%

56.11M

Total Equity

38%

3Y+76.0%

5Y+116.0%

10Y+4403.0%

DiaMedica Therapeutics Inc. Funding & Solvency Profile

DMAC · NASDAQ

Current Assets

Cash & Cash Equivalents15.65M

Net Receivables258.00K

Inventory0.00

Other Current Assets481.00K

Total Current Assets61 M

Non-Current Assets

Property, Plant & Equipment342.00K

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets400.00K

Total Non-Current Assets742 K

Total Assets

61.37M

Financial Health Analysis

Current Ratio

11.81x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.09x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

55 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

99% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

DiaMedica Therapeutics Inc. Balance Sheet

DMAC • NASDAQ

DiaMedica Therapeutics Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011	Dec 2010	Dec 2009	Dec 2008	Dec 2007	Dec 2006
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	15.6M	3M	4.5M	4.7M	4.7M	7.4M	3.9M	16.8M	1.4M	1.7M	165.7K	203.8K	2.5M	2.3M	2.7M	2.8M	629.5K	2.5M	3.5M	269.6K
Short-Term Investments	44.2M	41.1M	48.4M	28.8M	40.4M	20.1M	4M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Cash & Short-Term Investments	59.9M	44.1M	52.9M	33.5M	45.1M	27.5M	7.9M	16.8M	1.4M	1.7M	165.7K	203.8K	2.5M	2.3M	2.7M	2.8M	629.5K	2.5M	3.5M	269.6K
Net Receivables	258K	236K	369K	82K	0.0	0.0	823K	646K	80K	52K	9.6K	8.4K	0.0	0.0	50.4K	221K	47.9K	31.1K	95.5K	57.1K
Accounts Receivables	8K	1K	71K	2K	0.0	0.0	17K	24K	80K	0.0	379.0	8.4K	706.0	2.8K	6.6K	126.1K	15.9K	31.1K	95.5K	57.1K
Other Receivables	250K	235K	298K	80K	0.0	0.0	793K	622K	0.0	52K	9.6K	0.0	14.4K	20.5K	43.7K	94.9K	47.8K	0.0	0.0	0.0
Inventory	0.0	0.0	0.0	0.0	0.0	0.0	88K	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Prepaids	0.0	0.0	411K	251K	84K	64K	88K	369K	61K	65.2K	32.9K	53.9K	81.7K	104.3K	33.7K	83.8K	17.2K	42K	50.1K	9.9K
Other Current Assets	481K	227K	0.0	0.0	243K	350K	-41K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Current Assets	60.6M	44.6M	53.7M	33.8M	45.4M	27.9M	8.8M	18M	1.5M	1.9M	208.1K	266K	2.6M	2.5M	2.7M	3.1M	694.6K	2.5M	3.6M	336.5K
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	342K	427K	485K	560K	112K	174K	217K	96K	37K	19.4K	14.3K	15.6K	19.7K	6.6K	7.5K	8.9K	87.9K	99.8K	154.4K	13.1K
Intangible Assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	269.3K	1.4M	3.6M	5.9M	463K	356.8K	535.7K	357.2K
Goodwill & Intangible Assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	269.3K	1.4M	3.6M	5.9M	463K	356.8K	535.7K	357.2K
Other Non-Current Assets	400K	1.3M	0.0	0.0	0.0	0.0	0.0	271K	271K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Non-Current Assets	742K	1.7M	485K	560K	112K	174K	217K	367K	308K	19.4K	14.3K	15.6K	288.9K	1.4M	3.6M	5.9M	550.9K	456.6K	690K	370.3K
Total Assets	61.4M	46.3M	54.2M	34.4M	45.6M	28.1M	9.1M	18.3M	1.8M	1.9M	222.4K	281.6K	2.9M	3.8M	6.3M	9.1M	1.2M	3M	4.3M	706.9K
LIABILITIES
CURRENT LIABILITIES
Total Payables	1.5M	940K	926K	734K	509K	1.1M	182K	517K	519K	250K	812.8K	998.6K	372.9K	1.2M	227.8K	0.0	0.0	0.0	272.4K	53.3K
Accounts Payable	1.5M	940K	926K	734K	509K	1.1M	182K	483K	513K	250K	674.1K	960K	372.1K	1.1M	139.1K	0.0	0.0	0.0	272.4K	53.3K
Other Payables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	34K	6K	0.0	138.6K	38.6K	795.0	59.3K	88.6K	0.0	0.0	0.0	0.0	0.0
Accrued Expenses	0.0	0.0	1M	698K	966K	864K	419K	357K	45K	279K	220.7K	1.8M	954.4K	331.4K	136.8K	0.0	0.0	0.0	0.0	0.0
Short Term Debt	0.0	0.0	0.0	0.0	0.0	0.0	60K	0.0	0.0	0.0	261.4K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital Lease Obligations (Current)	112K	103K	83K	69K	49K	65K	60K	5K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax Payables	0.0	0.0	0.0	0.0	0.0	0.0	52K	34K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	34K	0.0	-200.5K	33K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Current Liabilities	3.5M	4.3M	766K	667K	0.0	0.0	597K	417K	439K	98K	-264.3K	-998.6K	197.2K	59K	0.0	554.1K	197.9K	218K	0.0	0.0
Total Current Liabilities	5.1M	5.4M	2.8M	2.2M	1.5M	2M	1.3M	1.3M	1M	627K	1.1M	1.8M	1.5M	1.6M	364.6K	554.1K	197.9K	218K	272.4K	53.3K
NON-CURRENT LIABILITIES
Long Term Debt	0.0	0.0	0.0	0.0	0.0	0.0	118K	18K	0.0	0.0	389.2K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	0.0	0.0	0.0	0.0	0.0	0.0	-118K	-18K	0.0	0.0	-1K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Non-Current Liabilities	128K	237K	317K	400K	3K	53K	118K	18K	0.0	0.0	388.2K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital Lease Obligations	240K	340K	400K	469K	52K	118K	178K	23K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	5.3M	5.6M	3.1M	2.6M	1.5M	2.1M	1.4M	1.3M	1M	627K	1.5M	1.8M	1.5M	1.6M	364.6K	554.1K	197.9K	218K	272.4K	53.3K
SHAREHOLDERS' EQUITY
Treasury Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Common Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	41M	28.1M	32.3K	33.6K	30.2K	0.0	0.0	0.0	0.0	0.0	0.0
Additional Paid-In Capital	228.8M	180.7M	166.6M	128.1M	126.6M	94.9M	64.2M	63M	41M	6.2M	3.9M	4.5M	3.9M	3.5M	2.6M	1.8M	1.4M	903.4K	938.4K	3.7M
Retained Earnings	-172.8M	-140M	-115.6M	-96.2M	-82.5M	-68.9M	-56.6M	-46M	-40.2M	-46.7M	-34M	-38.9M	-37.1M	-31.8M	-21.2M	-14.9M	-10.2M	-6.6M	-5.9M	-3M
Accumulated Other Comprehensive Income/Loss	50K	23K	6K	-74K	-51K	-2K	2K	-24K	610.9K	587.1K	-20.9K	-20.1K	-19.2K	-15.8K	-10.7K	-8K	-95K	-57.4K	91.4K	-23.1K
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-610.9K	0.0	11.3M	-559.7K	-83.9K	30.5M	-73.3K	21.8M	9.8M	8.5M	9M	28K
Total Stockholders' Equity	56.1M	40.7M	51.1M	31.8M	44M	26M	7.6M	17M	799K	1.2M	-1.2M	-1.5M	1.4M	2.3M	6M	8.5M	1M	2.8M	4.1M	653.6K
Total Equity	56.1M	40.7M	51.1M	31.8M	44M	26M	7.6M	17M	799K	1.2M	-1.2M	-1.5M	1.4M	2.3M	6M	8.5M	1M	2.8M	4.1M	653.6K
SUMMARY
Total Liabilities & Equity	61.4M	46.3M	54.2M	34.4M	45.6M	28.1M	9.1M	18.3M	1.8M	1.9M	222.4K	281.6K	2.9M	3.8M	6.3M	9.1M	1.2M	3M	4.3M	706.9K
Total Investments	44.2M	41.1M	48.4M	28.8M	40.4M	20.1M	4M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Debt	240K	340K	400K	469K	52K	118K	178K	23K	0.0	200.5K	649.2K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net Debt	-15.4M	-2.7M	-4.1M	-4.3M	-4.7M	-7.3M	-3.7M	-16.8M	-1.4M	-1.5M	483.5K	-203.8K	-2.5M	-2.3M	-2.7M	-2.8M	-629.5K	-2.5M	-3.5M	-269.6K
Shares Outstanding	51,688,913	51,688,913	51,688,913	51,688,913	51,688,913	51,688,913	51,688,913	51,688,913	51,688,913	51,688,913	51,688,913	51,688,913	51,688,913	51,688,913	51,688,913	51,688,913	51,688,913	51,688,913	51,688,913	51,688,913

SEC Filings

DMAC - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 21, 2026	May 20, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 06, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 06, 2026	May 06, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 01, 2026	May 20, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 31, 2026	March 30, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 30, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	January 05, 2026	January 05, 2026	2026	View Filing
8-K 8-K 2025 N/A	December 18, 2025	December 18, 2025	2025	View Filing
10-Q 10-Q 2025 Q3 Q3	November 12, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 12, 2025	November 12, 2025	2025	View Filing

Showing 1 to 10 of 131 filings

Related Guides

Blog Categories

Continue your DMAC research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.